Abstracts tagged "Systemic sclerosis"

Abstract Number: 0643 • ACR Convergence 2023
Progression of Interstitial Lung Disease in Systemic Sclerosis Does Not Predict Further Progression
Anna-Maria Hoffmann-Vold¹, Liubov Petelytska², Havard Fretheim¹, Trond Mogens Aaløkken³, Mike Becker⁴, Hilde Jenssen Bjørkekjær⁵, Cathrine Brunborg⁶, Cosimo Bruni⁷, Christian Clarenbach⁸, Phuong Phuong Diep⁹, Rucsandra Dobrota⁷, Michael Durheim¹⁰, Muriel Elhai¹¹, Thomas Frauenfelder¹², Suzana Jordan⁷, Emily Langballe¹³, Oyvind Midtvedt¹, Carina Mihai⁷, Oyvind Molberg¹⁴ and Oliver Distler⁷, ¹Oslo University Hospital, Oslo, Norway, ²Bogomolets National Medical University, Kyiv, Ukraine, ³Dept of Radiology, Oslo University Hospital, Oslo, Norway, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁵Department of Rheumatology, Hospital of Southern Norway, Kristiansand & University of Oslo, Institute of Clinical Medicine, Oslo, Norway, ⁶Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, ⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Dept of Pulmonology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁹Dept of Respiratory diseases, University Hospital Oslo, Oslo, Norway, ¹⁰Dept of Respiratory diseases, Oslo University Hospital, Oslo, Norway, ¹¹University Hospital zurich, University of Zurich, Zurich, Switzerland, ¹²Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹³Universitetet i Oslo, Oslo, Norway, ¹⁴Dept of Rheumatology, University Hospital Oslo, Oslo, Norway
Background/Purpose: In clinical practice, we often wait for progression of interstitial lung disease (ILD) in systemic sclerosis (SSc) to initiate or escalate therapy. Similarly, progressive…
Abstract Number: 0663 • ACR Convergence 2023
Vaccine-Preventable Diseases in Hospitalized Patients with Systemic Sclerosis: A Nationwide Cohort Analysis
Saman Tanveer, Chun Pan and Faria Sami, John H. Stroger Jr. Hospital of Cook County, Chicago, IL
Background/Purpose: Connective tissue disorders, including systemic sclerosis (SSc), are associated with an increased risk of infections. Infections are the most common diagnosis during hospitalizations and…
Abstract Number: 0938 • ACR Convergence 2023
Deconvolution of the Molecular Signature of Very Early Diagnosis of Systemic Sclerosis (VEDOSS) and Established Disease: A Biomarker Blueprint of Scleroderma Disease Continuum
Sunhwa Kim¹, Thierry Sornasse², Vishal Kakkar³, Rebecca Ross⁴, Yingtao Bi⁵, Hengcheng Hu², Lisa Hazelwood², Lauren Reinke-Breen⁶, jozsef karman⁷, Chris Butler², Jennifer Van Camp² and Francesco Del Galdo⁸, ¹AbbVie, Inc., South San Francisco, CA, ²AbbVie, Inc., North Chicago, IL, ³University of Leeds, Leeds, United Kingdom, ⁴Medicine and Health, University of Leeds, Leeds, United Kingdom, ⁵AbbVie, Inc., Worcester, MA, ⁶AbbVie, Inc., Vernon Hills, IL, ⁷AbbVie, Inc., San Francisco, CA, ⁸University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease that affects multiple organs asynchronously, leading to highly variable fibrotic damage and consequent increased morbidity and mortality.…
Abstract Number: 0963 • ACR Convergence 2023
Anti-Topoisomerase Antibody in dcSSc: Unravelling Its Intracellular Effects in Systemic Sclerosis
Maithri Aspari¹, Josephine Geertsen Keller-Socin¹, Stinne Greisen², Esben Naeser³, Klaus Soendergaard⁴, Birgitta R Knudsen⁵, Voon Ong⁶, Christopher Denton⁷, David Abraham⁷ and Bent Deleuran¹, ¹Aarhus University, Aarhus, Denmark, ²Aarhus University/Aarhus University Hospital, Aarhus, Denmark, ³Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁴Aarhus University Hospital, Aarhus, Denmark, ⁵Institute for molecular Biology, Aarhus University, Aarhus, Denmark, ⁶UCL Medical School Royal Free Campus, London, United Kingdom, ⁷University College London, London, United Kingdom
Background/Purpose: The presence of autoantibodies, especially directed towards topoisomerase I (ATA), in diffuse cutaneous Systemic Sclerosis (dcSSc) is known to be associated with severe clinical…
Abstract Number: 1529 • ACR Convergence 2023
Mycophenolate Mofetil Use in Clinical Practice: Persistence on Therapy and Long-term Adverse Events in a Multicentric Cohort of Scleroderma Patients
Silvia Bosello¹, enrico De Lorenzis¹, lucrezia verardi¹, gerlando Natalello¹, pier giacomo Cerasuolo¹, Stefano Di Donato², Greta Pellegrino³, Giacomo De Luca⁴, Corrado Campochiaro⁵, Gemma Lepri⁶, Laura Cometi⁷, Fabio Cacciapaglia⁸, Giuseppe Armetano⁹, Marco De Pinto¹⁰, Francesca Motta¹¹, Maria De Santis¹¹, Dilia Giuggioli¹², Nicoletta Del Papa⁹, Florenzo Iannone¹³, Serena Guiducci⁷, valeria Riccieri¹⁴, Maria Antonietta D'Agostino¹ and Francesco Del Galdo², ¹Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy, ²University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom, ³Department of Rheumatology, La Sapienza University of Rome, Rome, Italy, ⁴Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milano, Italy, ⁵IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, ⁶Department of Experimental and Clinical medicine, Division of Rheumatology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy, ⁷University of Florence, Unit of Rheumatology Azienda Ospedaliera Careggi, Florence, Italy, ⁸Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari, Bari, Italy, ⁹Scleroderma Clinic, Dipartimento di Reumatologia, ASST Gaetano Pini CTO, Milano, Italy, ¹⁰Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto, Università di Modena e Reggio Emilia, Modena, Modena, Italy, ¹¹Reumatologia e Immunologia Clinica, IRCCS Humanitas Research Hospital, Humanitas University, Rozzano, Milan, Italy, ¹²Scleroderma Unit, Rheumatology Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy, ¹³Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ¹⁴Department of Clinical, Internal and Cardiovascular Specialities, Sapienza University of Rome, Roma, Italy
Background/Purpose: Mycophenolate mofetil (MMF) is a first-line immunosuppressant treatment for systemic sclerosis (SSc), particularly for patients with interstitial lung disease (ILD) and diffuse skin involvement.…
Abstract Number: 1930 • ACR Convergence 2023
Blue Digit Syndrome as the Initial Presentation of Various Diseases: A Case Series
Raquel Ugena García¹, Juan José Lluch Galcerá², Cristina Calomarde Gomez¹, Ivette Casafont-Sole³ and Lourdes Mateo Soria², ¹Rheumatology department. Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Hospital Germans Trias i Pujol, Badalona, Spain, ³Hospital Universitari Germans Trias i Pujol, Badalona, Spain
Background/Purpose: Blue Digit Syndrome (BDS) represents the cutaneous manifestation of numerous diseases that cause blue discoloration in one or more fingers in the absence of…
Abstract Number: 2593 • ACR Convergence 2023
FT011 for the Treatment of Systemic Sclerosis. Results from a Phase II Study
Christopher Denton¹, Wendy Stevens², Nicole Kruger³, Michelle Papadimitriou⁴, Fay Khong⁴, Michelle Bradney³, Darren Kelly⁴ and Robert Lafyatis⁵, ¹University College London, London, United Kingdom, ²Department of Rheumatology, St Vincent's Hospital Melbourne, Fitzroy, Australia, ³Certa Therapeutics, Melbourne, Australia, ⁴Certa Therapeutics and Melbourne University, Melbourne, Australia, ⁵University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease characterized by vascular damage, inflammation, and fibrosis of the skin and organs, with no approved disease modifying…
Abstract Number: 0129 • ACR Convergence 2023
Rising Incidence and High Mortality of Systemic Sclerosis: A Population-based Cohort Study (2010-2020)
Anukul Karn¹, Sara Achenbach², Alicia Hinze³, Cynthia Crowson¹ and Ashima Makol², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, Rochester, MN, ³Mayo Clinic - Rochester, MN, Rochester, MN
Background/Purpose: Systemic Sclerosis (SSc) is a rare chronic inflammatory disease characterized by immune-mediated dysfunction, vasculopathy and widespread internal organ fibrosis; and the highest case fatality…
Abstract Number: 0623 • ACR Convergence 2023
Nailfold Capillaroscopy in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Treated with Nintedanib
Vanessa Smith¹, Christopher Denton², Ariane Herrick³, Carina Ittrich⁴, Margarida Alves⁵ and Maurizio Cutolo⁶, ¹Ghent University Hospital, Gent, Belgium, ²University College London, London, United Kingdom, ³University of Manchester, Salford, United Kingdom, ⁴Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, Biberach an der Riss, Germany, ⁵Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁶Laboratory of Experimental Rheumatology, Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic, Genova, Italy
Background/Purpose: Microvascular damage is part of the pathogenesis of systemic sclerosis and is associated with internal organ involvement. Nintedanib is a tyrosine kinase inhibitor approved…
Abstract Number: 0644 • ACR Convergence 2023
Prediction of Stable SSc-ILD Depends on Definition of ILD Progression
Anna-Maria Hoffmann-Vold¹, Liubov Petelytska², Havard Fretheim¹, Trond Mogens Aaløkken³, Mike Becker⁴, Cathrine Brunborg⁵, Cosimo Bruni⁶, Christian Clarenbach⁷, Phuong Phuong Diep⁸, Rucsandra Dobrota⁶, Michael Durheim⁹, Muriel Elhai¹⁰, Thomas Frauenfelder¹¹, Suzana Jordan⁶, Emily Langballe¹², Carina Mihai⁶, Oyvind Midtvedt¹, Oyvind Molberg¹³ and Oliver Distler⁶, ¹Oslo University Hospital, Oslo, Norway, ²Bogomolets National Medical University, Kyiv, Ukraine, ³Dept of Radiology, Oslo University Hospital, Oslo, Norway, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁵Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, ⁶Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁷Dept of Pulmonology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Dept of Respiratory diseases, University Hospital Oslo, Oslo, Norway, ⁹Dept of Respiratory diseases, Oslo University Hospital, Oslo, Norway, ¹⁰University Hospital zurich, University of Zurich, Zurich, Switzerland, ¹¹Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹²Universitetet i Oslo, Oslo, Norway, ¹³Dept of Rheumatology, University Hospital Oslo, Oslo, Norway
Background/Purpose: Progression of interstitial lung disease (ILD) reduces long-term survival in patients with systemic sclerosis (SSc), and aggressive treatment and tight monitoring should be considered.…
Abstract Number: 0666 • ACR Convergence 2023
Troponin I Levels in Systemic Sclerosis Patients with Myocardial Involvement
Eva Hoekstra¹, Sophie Liem¹, Nivine Levarht¹, Cynthia Fehres¹, Saad Ahmed¹, Nina Ajmone Marsan², Thomas Huizinga¹ and Jeska de Vries-Bouwstra¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Department of Cardiology, Heart Lung Centre, Leiden University Medical Centre, Leiden, Netherlands
Background/Purpose: As primary myocardial involvement in systemic sclerosis (SSc) is associated with worse prognosis, research on diagnostic tools for recognition is essential. Troponin I was…
Abstract Number: 0940 • ACR Convergence 2023
A Novel Therapeutic Opportunity in Systemic Sclerosis: The Fibrolytic Activities of a Specialized Macrophage Secretome
Françis Bonnefoy¹, Susanne Behlke² and Sylvain Perruche¹, ¹Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Institute/MedINNPharma, Besançon, France, ²MedINNPharma, Besançon, France
Background/Purpose: Systemic sclerosis (SSc) a complex and rare immune-mediated connective tissue disorder characterized by microvascular damage, inflammatory cell infiltration, and excessive deposition of extracellular matrix…
Abstract Number: 1035 • ACR Convergence 2023
Diagnostic and Educational Utility of an Ultrasound Protocol for Evaluation of Hand Pain in Systemic Sclerosis
Meridith Balbach, Tracy Frech, Nicholson Chadwick, Kevin Byram and Erin Chew, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Hand impairment is a prevalent issue among systemic sclerosis (SSc) patients and contributes to disability and diminished quality of life. Managing hand pain can…
Abstract Number: 1533 • ACR Convergence 2023
Long-term Use of Rituximab in Systemic Sclerosis: A Real-life Italian Multicentre Study
Giacomo De Luca¹, Corrado Campochiaro², Fabio Cacciapaglia³, Nicoletta Del Papa⁴, Elisabetta Zanatta⁵, Paolo Airò⁶, Maria Grazia Lazzaroni⁶, Dilia Giuggioli⁷, Maria De Santis⁸, Gabriella Alonzi⁹, Stefano Stano¹⁰, Marco Binda⁵, Beatrice Moccaldi⁵, Antonio Tonutti¹¹, Florenzo Iannone¹², Maria Antonietta D'Agostino⁹, Lorenzo Dagna¹³, marco Matucci Cerinic¹⁴ and Silvia Bosello¹⁵, ¹Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milano, Italy, ²IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, ³Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari, Bari, Italy, ⁴Scleroderma Clinic, Dipartimento di Reumatologia, ASST Gaetano Pini CTO, Milano, Italy, ⁵Rheumatology Unit, Padova University Hospital, Padova, Italy, ⁶Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, ⁷Scleroderma Unit, Rheumatology Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy, ⁸Reumatologia e Immunologia Clinica, IRCCS Humanitas Research Hospital, Humanitas University, Rozzano, Milan, Italy, ⁹Scleroderma Unit, Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ¹⁰Rheumatology Unit - DiMePRe-J University of Bari, Bari, Italy, ¹¹Humanitas University and Humanitas Research Hospital, Rozzano, Italy, ¹²Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ¹³Department of Internal Medicine, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy, ¹⁴Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, ¹⁵Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy
Background/Purpose: Rituximab(RTX) has been used for the management of systemic sclerosis(SSc). Its efficacy has been recently confirmed in a phase III clinical trial with extension…
Abstract Number: 2094 • ACR Convergence 2023
Increasing Collaboration, Education, and Awareness of Scleroderma Through an Interprofessional Education Program: Emphasizing the Importance of a Multidisciplinary Team and the Patient as the Primary Educator
Corey Fellon¹, Hannah Bowen² and Lee Shapiro³, ¹Albany Medical College, Albany, NY, ²Steffens Scleroderma Foundation, Batavia, NY, ³Albany Medical College, Stillwater, NY
Background/Purpose: Scleroderma is a condition that can affect almost every organ system and thus requires an interprofessional team to optimally manage symptoms and improve patient…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].